The effect of heparin rinse on the biocompatibility of continuous veno-venous hemodiafiltration.
The aims of our cross-over randomized study were (1) to assess hemostasis in patients with acute renal failure (ARF) and (2) to determine whether or not the generally recommended heparin rinse of the extracorporeal circuit (ECC) prior to the procedure affects thrombogenicity, complement activation, and leukocyte count in blood during continuous venovenous hemodiafiltration (CVVHDF). Eleven critically ill ARF patients were treated, in random order, using CVVHDF in postdilution setup following ECC rinse with saline (A) with heparin at a concentration of 2,000 IU/L (10 procedures), (B) with heparin at a concentration of 10,000 IU/L (7 procedures), and (C) without heparin (9 procedures). Except for the rinse, anticoagulation therapy did not differ in individual patients during the procedures. Blood was withdrawn before, and at minutes 15, 60, and 360 invariably at diafilter inlet and outlet. Compared with healthy individuals, patients showed lower blood thrombocyte counts (153 vs 233*10(9)/L, p<0.01, arithmetic means, Student's t test), longer aPTT (44 vs 36 s, p<0.05), higher plasma levels of heparin (0.1 vs 0.0 U/mL, p<0.05), D-dimer (1129 vs 36 ng/mL, p<0.001) and beta-thromboglobulin (BTG) (159 vs 37 U/mL, p<0.001) prior to CVVHDF. The comparison of procedures with different rinsing technique did not reveal any significant difference in their effects on blood thrombocyte and leukocyte counts, aPTT, plasma levels of heparin, BTG, thrombin-antithrombin III complexes, D-dimer, or the C5a complement component.


CONCLUSIONS
(1) Patients indicated for CVVHDF show impaired hemostasis involving thrombocytes, coagulation, and fibrinolysis, (2) no beneficial effect of heparin rinse on CVVHDF ECC thrombogenicity, complement activation or blood leukocyte counts was demonstrated.
Department of Internal Medicine I, Charles University Medical School, Pilsen, Czech Republic. opatrny@fnplzen.cz
K
K
Opatrný
K
K
Polanská
A
A
Krouzecký
L
L
Vít
I
I
Novák
E
E
Kasal
D058186:Acute Kidney Injury / Q000097:blood / Q000503:physiopathology* / Q000628:therapy*; D000368:Aged; D003167:Complement Activation / Q000187:drug effects*; D016638:Critical Illness; D018592:Cross-Over Studies; D004344:Drug Incompatibility; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D017583:Hemodiafiltration; D015312:Hemodialysis Solutions / Q000494:pharmacology*; D006487:Hemostasis / Q000187:drug effects*; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013927:Thrombosis / Q000097:blood / Q000503:physiopathology*
D005343:Fibrinolytic Agents; D015312:Hemodialysis Solutions; D006493:Heparin